News Releases
November 15, 2017 :
TREMFYA™ is the first approved biologic that selectively blocks interleukin-23interleukin-23
TORONTO, Nov. 15, 2017 /CNW/ - Janssen Inc. announced today that Health Canada has approved TREMFYA™ (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.1 TREMFYA™ is the first approved biologic therapy that selectively blocks interleukin-23 (IL-23), a key inflammatory protein that plays an important role in plaque psoriasis.1,2
